17.08  0.3 (1.79%)		01-21 10:09
Open: 14.64 High: 17.3295 Volume: 463,518		Pre. Close: 16.78 Low: 14.64 Market Cap: 1,661(M)

Short term
Mid term
Targets	6-month :	20.01	1-year :	23.38
Resists	First :	17.13	Second :	20.01
Pivot price	0
Supports	First :	14.5	Second :	12.88
MAs	MA(5) :	15.42	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	17.13	Low :	12.88

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DFTX ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	17.16 - 17.23	17.23 - 17.29
Low:	14.46 - 14.53	14.53 - 14.59
Close:	16.64 - 16.77	16.77 - 16.89

Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Tue, 20 Jan 2026
Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care - Business Wire

Fri, 16 Jan 2026
Assessing Mind Medicine (MindMed) (DFTX) Valuation After Rebrand To Deinium Therapeutics And Pipeline Progress - simplywall.st

Tue, 13 Jan 2026
Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026 - Business Wire

Tue, 13 Jan 2026
MindMed’s Rebrand To Definium Therapeutics And DT120 Pivot Could Be A Game Changer For Mind Medicine (MindMed) (MNMD) - simplywall.st

Mon, 12 Jan 2026
Definium points the way forward as MindMed drops old identity - Fierce Pharma

Mon, 12 Jan 2026
MindMed Rebrands to Definium Therapeutics, Advancing a Leading Late-Stage Psychiatry Pipeline with Three Phase 3 Readouts Expected in 2026 - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	97 (M)
Shares Float	98 (M)
Held by Insiders	0.5 (%)
Held by Institutions	41.6 (%)
Shares Short	15,050 (K)
Shares Short P.Month	12,350 (K)

EPS	-1.99
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.7
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-34 %
Return on Equity (ttm)	-85.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.57
Qtrly Earnings Growth	0 %
Operating Cash Flow	-114 (M)
Levered Free Cash Flow	-48 (M)

PE Ratio	-8.48
PEG Ratio	0
Price to Book value	9.87
Price to Sales	0
Price to Cash Flow	-14.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.